This is a preview of subscription content, log in via an institution to check access.
Notes
Their work was financially supported by Boehringer Ingelheim.
Reference
Zheng Y, et al. Comparison of the Cost-effectiveness of New Oral Anticoagulants for the Prevention of Stroke and Systemic Embolism in Atrial Fibrillation in a UK Setting. Clinical Therapeutics : 23 Oct 2014. Available from: URL: http://doi.org/10.1016/j.clinthera.2014.09.015
Rights and permissions
About this article
Cite this article
Dabigatran etexilate economically dominates in the UK. PharmacoEcon Outcomes News 718, 18 (2014). https://doi.org/10.1007/s40274-014-1783-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-014-1783-1